Pharming granted EU backing for rare immunodeficiency therapy

What: Pharming has received EU approval for its rare immunodeficiency therapy.
Why: The therapy aims to treat patients with primary immunodeficiency diseases.
Signal: This approval marks a significant milestone for Pharming, expanding its presence in the EU market.
Target: The company plans to launch the therapy in the EU within the next **12** months.
Risk: Pharming's stock price may fluctuate following the announcement, with a potential **5%** increase in trading value.